Navigation Links
Panacea Announces the Availability of PC Detect(sm) for Prostate Cancer Screening

Panacea Pharmaceuticals, Inc. announced today that PC Detect(sm), the Company's prostate cancer screening test, is now available from Panacea Laboratories. PC Detect(sm) is a simple blood test, which is recommended as an adjunct to the prostate specific antigen (PSA) test and the digital rectal examination (DRE), the currently recommended prostate cancer screening methods.

The addition of PC Detect(sm) to the current screening methods is expected to improve the diagnosis of prostate cancer among men with prostate specific antigen (PSA) values below the currently recommended level for prostate biopsy. Panacea Laboratories, a division of Panacea Pharmaceuticals, is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA).

The blood sample can be ordered by any physician and sent to Panacea for testing. The Company anticipates submission of a Pre-Market Application (PMA) to the U.S. Food and Drug Administration later in 2007 to facilitate development of a PC Detect(sm) kit, which will be commercialized through clinical laboratories around the country.

Prostate cancer is currently the most prevalent form of cancer in men and the second leading cause of male cancer deaths in the United States. The standard-of-care screening tools for prostate cancer used by physicians to determine whether to refer a patient for a prostate biopsy include the prostate-specific antigen (PSA) and the digital rectal examination (DRE).

The American Cancer Society (ACS) recommends that a PSA blood test and DRE be performed annually in men > 50 years old. However, the predictive value of an elevated PSA and/or an abnormal DRE is limited. PSA is a tissue-specific protein and has been shown to be elevated in patients with benign prostatic conditions as well as in patients with prostate cancer. About 25% of men recommended for prostate biopsy with a PSA of 4-10 ng/mL will be found to have cancer on biopsy, and a PSA > 4.0 ng/mL has a sensitivity of 46% for identification of patients who will be found to have prostate cancer over the next 10 years. According to the ACS, patients with a PSA > 10 ng/mL should undergo a prostate biopsy since >50% of these men are likely to have cancer.

However, men with PSA levels of 2-4 ng/mL are not routinely recommended to have prostate biopsies, despite the fact that almost 24% of men with PSA levels of 2.1 to 3.0 ng/mL will be diagnosed with prostate cancer as will almost 27% of men with PSA levels of 3.1 to 4.0 ng/mL, according to a study by Thompson et.al., published in 2004 in the New England Journal of Medicine.

PC Detect(sm) has demonstrated a sensitivity of greater than 90% in identifying men with prostate cancer who have PSA levels of 2-4 ng/mL. Punglia et.al. (2003) found that if prostate biopsies were performed only when the PSA level is greater than 4.0 ng/mL, 82% of cancers would be missed in those who are younger than 60 years of age, and 65% would be missed in those who are 60 or older. As such, PC Detect(sm) may aid in the identification of a significant number of men with prostate cancer at an earlier stage and facilitate improved outcomes.

PC Detect(sm), a CLIA laboratory service, is a new method for screening a patient's serum to help determine the likelihood that prostate cancer is present. PC Detect(sm) provides information to differentiate prostate cancer from benign conditions and to help guide both the physician and the patient regarding further diagnostic testing and management by measuring blood levels of Human Aspartyl (Asparaginyl) beta-Hydroxylase (HAAH), a cancer biomarker. HAAH has been established as an excellent biomarker for many types of cancer, including prostate cancer. The protein is typically undetectable in sera from cancer-free individuals, thus, an elevated serum protein level of HAAH is highly diagnostic for cancer.

"The addition of PC Detect(sm) to sta ndard-of-care prostate cancer screening, with PSA and DRE, should significantly enhance a physician's ability to identify men at high-risk of having prostate cancer, even in those with PSA levels of 2-4 ng/mL," commented Pamela Jo Harris, MD, Vice President, Medical and Clinical Affairs at Panacea. "We are confident that the addition of PC Detect(sm) will help internists, family practitioners, and urologists better assess the need for a patient to have a prostate biopsy and to identify those likely to have prostate cancer."


'"/>




Related medicine news :

1. Panacea Biotech To Market Anthrax Vaccine
2. Panacea Biotec In-Licenses FMD Vaccine
3. Panacea To Market Measles Vaccine In India
4. Websites That Offer Panacea for Eating Disorders may Be Dangerous
5. Ramdoss Announces Introduction of RCH-II
6. Britain Announces Third Transfusion Related Mad Cow Case
7. Tibet Announces the Dalai Lama’s Tour of South Americ
8. Indian PM Announces Of Setting Up India Study Center At Tashkent
9. PowderMed Announces Needle-Less Flu Vaccine
10. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
11. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 26, 2016 One of Australia,s ... formation of a new biotechnology company, Noxopharm Limited [ABN 50 608 ... IPO and to list on the ASX. Noxopharm is ... to enter a Phase 1 clinical study later this year. ... one of the biggest problems facing cancer patients - the ability ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology: